(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Amplifying Cash The executives: The Upsides and downsides of Various Ledgers- Two die and thousands homeless after flooding hits Russia's Dagestan
- China’s new condom tax will prove no effective barrier to country’s declining fertility rate
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- How Skoda Lost Its Biggest Market In Just Seven Years
- The most effective method to Distinguish the Best Material Organization in Your Space
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Lula’s former human rights minister formally accused of sexual misconduct
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
